Omega-3 (EPA/DHA)

• Lowering high triglycerides (high-dose, strongly supported)
• Secondary cardiovascular risk reduction with prescription high-dose EPA (contested)
• Anti-inflammatory adjunct (modest, mixed)
• DHA in pregnancy for fetal brain and eye development
• Rheumatoid arthritis symptom support (modest)
• Cognitive aging support (weak)

EPA and DHA, the long-chain omega-3 fatty acids, incorporate into cell membrane phospholipids and serve as precursors to specialized pro-resolving mediators (resolvins, protectins, maresins) that actively terminate inflammation. EPA dominates the cardiovascular and anti-inflammatory profile; DHA is structurally critical for retinal and neuronal membranes, particularly in fetal and infant development. The mechanism is well-characterized; the question has always been whether supplementation-level doses produce population-level outcome change.

Omega-3 absorption is meaningfully enhanced by taking with the fattiest meal of the day, these are fat-soluble esters that depend on bile and lipase for absorption. Divided dosing (twice daily) maintains higher steady-state plasma levels than single doses. The right dose depends on indication: 1g/day combined EPA+DHA is the "general wellness" maintenance dose with modest expected benefit; 2-4g/day is the inflammatory/triglyceride dose with meaningful clinical effect; 4g/day approaches the REDUCE-IT cardiovascular dose where prescription-grade EPA becomes practical. Quality matters substantially, oxidized fish oil produces measurable lipid peroxides that may negate the anti-inflammatory benefit. Look for low TOTOX values (oxidation marker) on Certificate of Analysis.

General wellness

1g/day combined EPA+DHA, with fatty meal

Hypertriglyceridemia

3-4g/day, divided, high-EPA preferred

Pregnancy DHA

200-300mg DHA/day; coordinate with OB-GYN

Depression adjunct

1-2g/day EPA-dominant ratio

Food state

With fatty meal, non-negotiable for adequate absorption

Divided dosing

Twice daily at 2g+/day for steady-state

Pre-surgery

Discontinue 7-14 days before elective procedures at high doses

Quality

TOTOX <20 on Certificate of Analysis; molecular distillation

• Triglyceride-Form Fish Oil

  Rating: gold

  The natural ester form found in fish. Better absorbed than ethyl ester form (Dyerberg 2010 showed ~70% higher absorption). The form used in most premium products and the form closer to dietary fish. Cost premium versus ethyl ester is modest and worth it for most users.

• Ethyl Ester Fish Oil

  Rating: caution

  Cheaper to manufacture through concentration of fish oil triglycerides. Absorption is ~30% lower than triglyceride form when taken without dietary fat; difference narrows with fatty meal co-administration. Most low-tier consumer products use ethyl ester. Functional but inferior bioavailability.

• Re-esterified Triglyceride (rTG)

  Rating: gold

  Ethyl ester converted back to triglyceride form during processing, captures concentration benefits while restoring superior absorption. Premium brands (Nordic Naturals, Carlson's) use this. Among the best-absorbed forms with high EPA/DHA concentration.

• Krill Oil (Phospholipid Form)

  Rating: good

  EPA/DHA bound to phospholipids rather than triglycerides. Some bioavailability advantage suggested in head-to-head trials; clinical outcome differences not consistently demonstrated. Includes astaxanthin antioxidant naturally. Substantially more expensive per gram of EPA+DHA than fish oil. Sustainability concerns about Antarctic krill harvest.

• Algal Oil (Vegan Source)

  Rating: gold

  Marine algae-derived. DHA-dominant historically; EPA-rich algal sources increasingly available. Functionally bioequivalent to fish-derived DHA in pharmacokinetic studies. The practical and ethical choice for vegan supplementation. Premium pricing.

• Cod Liver Oil

  Rating: good

  Traditional source. Provides EPA/DHA plus naturally occurring vitamins A and D. The vitamin A content can become problematic at chronic high doses (hypervitaminosis A); modern products often modify this. Useful traditional preparation; less concentrated than fish oil concentrates.

• Icosapent Ethyl (Vascepa), Prescription

  Rating: gold

  Pharmaceutical-grade pure EPA ethyl ester. FDA-approved for severe hypertriglyceridemia and cardiovascular risk reduction in specific populations. REDUCE-IT trial used 4g/day. Substantially more expensive than supplement-grade; prescription required.

• High-Dose Concentrate (90%+ EPA+DHA)

  Rating: good

  Premium concentrated formulations delivering 1g+ of EPA+DHA per softgel. Useful for high-dose protocols (4g/day cardiovascular use) where pill burden becomes inconvenient at standard 30% concentrations. Examples: WHC UnoCardio, Nordic Naturals ProOmega.

• Severe hypertriglyceridemia (>500 mg/dL)

  Strength of evidence for this group: strong

  The strongest case. Prescription icosapent ethyl (Vascepa) at 4g/day reduces triglycerides substantially and reduces cardiovascular events in REDUCE-IT. Supplement-grade can work at 3-4g/day combined EPA+DHA for triglyceride reduction with clinician oversight.

• Pregnancy and lactation (DHA)

  Strength of evidence for this group: strong

  DHA is essential for fetal brain and retinal development. Maternal supplementation supports infant cognitive outcomes; effect size modest but reproducible. Standard prenatal recommendations include 200-300mg DHA daily. Algal source is the practical vegan choice.

• Cardiovascular prevention in already-treated patients

  Strength of evidence for this group: weak

  The VITAL, ASCEND, and STRENGTH trials at 1g/day showed null or minimal effects on cardiovascular events in already-treated populations on statins/ACE inhibitors. The "fish oil prevents heart attacks at supplement doses" claim does not survive modern trial scrutiny.

• Documented inflammation / autoimmune

  Strength of evidence for this group: modest

  Modest reductions in inflammatory markers (CRP, IL-6) with chronic high-dose supplementation. May reduce NSAID use in rheumatoid arthritis. Effect sizes smaller than DMARDs; reasonable adjunct under specialist guidance.

• Cognitive aging and mild cognitive decline

  Strength of evidence for this group: modest

  Modest cognitive benefits in MCI and very mild dementia populations; smaller effect in healthy adults. Higher DHA content matters more than total dose for this endpoint. Evidence stronger in deficient (low fish intake) baseline populations.

• Major depressive disorder adjunct

  Strength of evidence for this group: modest

  Meta-analyses support 1-2g/day EPA-dominant supplementation as antidepressant adjunct, particularly in unipolar MDD. EPA-to-DHA ratio matters, predominantly EPA formulations show stronger signal than DHA-heavy products.

• Already-replete adults (regular fish consumers)

  Strength of evidence for this group: weak

  Adults eating 2+ servings of fatty fish weekly typically have adequate omega-3 status. Routine supplementation in this cohort produces small incremental changes without clearly demonstrated clinical benefit. Dietary fish remains the preferred source.

• Pre-surgery and bleeding-risk contexts

  Strength of evidence for this group: cautious

  High-dose omega-3 (>3g/day) modestly increases bleeding time. Most surgeons recommend discontinuation 1-2 weeks before elective procedures. Lower supplement doses (1-2g) have minimal clinical bleeding effect.

• Vitamin D3

  Interaction: synergy

  Both fat-soluble, both work better with fatty meal, practical co-administration. Mechanistically complementary for cardiovascular and immune endpoints. Common cardiovascular protocol pairing.

• CoQ10

  Interaction: synergy

  Mechanistically complementary for cardiovascular endpoints. Both fat-soluble; benefit from co-administration with fatty meal. Common heart-failure and statin-related protocols include both.

• Vitamin E

  Interaction: synergy

  Vitamin E protects against omega-3 oxidation in tissues. Many fish oil formulations include vitamin E as antioxidant preservative. Mechanistically appropriate combination.

• Aspirin (low-dose)

  Interaction: caution

  Additive antiplatelet activity. Most users tolerate low-dose aspirin (81mg) with standard omega-3 doses without clinical bleeding issues. Higher omega-3 doses (3g+) plus aspirin warrant clinician awareness, particularly perioperatively.

• Warfarin

  Interaction: caution

  Theoretical additive bleeding risk. Most clinical experience suggests modest interaction at standard doses; INR monitoring during initiation is appropriate. Higher omega-3 doses (3g+) more concerning.

• Direct oral anticoagulants (apixaban, rivaroxaban)

  Interaction: caution

  Less interaction than with warfarin but additive bleeding risk theoretically possible at higher omega-3 doses. Coordinate with cardiology for high-risk patients on DOACs.

• Statins

  Interaction: synergy

  Complementary lipid management, statins lower LDL, omega-3 lower triglycerides. Common cardiology protocol combination. No documented adverse interaction.

• Blood pressure medications

  Interaction: caution

  Omega-3 produces modest blood-pressure lowering at 2g+/day. Additive effect with antihypertensives can be clinically meaningful; monitor BP when initiating high-dose protocols.

• Chemotherapy

  Interaction: caution

  Theoretical concern about antioxidant interference with oxidative-mechanism chemotherapy. Coordinate with oncology rather than self-supplementing during active treatment.

The single most important quality marker is freshness, oxidized fish oil produces lipid peroxides that may negate benefit and contribute to "fishy reflux." Look for: TOTOX (total oxidation) value below 20 on Certificate of Analysis; IFOS (International Fish Oil Standards) 5-star certification; molecular distillation for heavy metal removal; transparent EPA and DHA content disclosure (not just "omega-3 1000mg"); recent manufacturing date and proper refrigeration; triglyceride or rTG form preferred over ethyl ester. Avoid: products that don't disclose EPA/DHA content separately; oils that smell strongly fishy on opening; bargain-priced products with no third-party testing; ethyl ester products without disclosure; products without manufacturing date disclosure.

Bang and Dyerberg's 1970s observation of low cardiovascular disease rates among Greenland Inuit despite extremely high fat intake launched the modern omega-3 era. The Greenland epidemiology has been substantially re-examined and reinterpreted in the decades since, but the initial signal drove fifty years of research and a multi-billion-dollar supplement category.

1. 1929Burr and Burr identify essential fatty acids
2. 1970sBang and Dyerberg report Greenland Inuit cardiovascular epidemiology
3. 2002American Heart Association recommends fish consumption for cardiovascular health
4. 2018REDUCE-IT publishes positive EPA result; ASCEND nulls
5. 2019VITAL primary cardiovascular endpoint null
6. 2020STRENGTH terminated for futility; Cochrane meta-analysis confirms supplementation-dose null

• Whether the REDUCE-IT EPA result generalizes outside the mineral-oil-placebo controversy.
• Why observational data and randomized trials at supplementation doses diverge so consistently.
• Optimal ratio of EPA to DHA for different indications (cardiovascular vs cognitive vs mood).
• Whether the absence of effect in modern trials reflects already-improved background care (statins, blood-pressure control) masking incremental benefit.

Universally available globally. Prescription-grade Vascepa (pure EPA, icosapent ethyl) is FDA-approved for hypertriglyceridemia and cardiovascular risk reduction in specific populations. Algal oil (DHA-dominant, vegan source) is increasingly available and matches fish-oil DHA on bioavailability.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Active fatty acids

EPA (eicosapentaenoic) + DHA (docosahexaenoic)

Maintenance dose

1-2g/day combined EPA+DHA

Hypertriglyceridemia dose

2-4g/day (often Rx)

Vegan source

Algal oil (primarily DHA)

Quality marker

Low TOTOX, molecular distillation

Rx form

Icosapent ethyl (Vascepa)

What follows is unfinished work on our side, not a finding about Omega-3 (EPA/DHA). A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.